Shanghai Xinhuanghe Pharmaceutical Co.,

Shanghai Xinhuanghe is a wholly owned subsidiary of Shanghai Chenpon, a dynamic pharmaceutical company with more than 38 commercialized products registered or supplied in 24 countries and strong sales coverage in China. Chenpon successfully registered and exported Parecoxib Sodium for Injection, the first generic version in Europe, to multiple countries, and developed its proprietary dry powder inhaler (DPI) platform, a technology commercialized by fewer than five companies worldwide, currently preparing to launch a Budesonide/Formoterol combination product.